Skip navigation

Navigate Country-Specific Regulations and Optimize Global Models for Stakeholder Collaboration, Program Design and Supply Equity

May 16-17, 2018
  • London, England

CBI’s Managed Access Programs is dedicated to the nuances and complexities of designing and implementing early access programs. Focused on global considerations for a variety of access management programs, including, but not limited to: Expanded Access Programs, Early Access Programs, Compassionate Use Programs, Named Patient Programs and Managed Access Programs.

A broad array of key stakeholders are coming together for an in-depth and meaningful discussion on Managed Access Programs where the implications, prevailing policies and current industry approaches are discussed in detail. Don’t miss the opportunity to join your peers and share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes.

Advanced Discussions on Key Issues and the Path Forward for Early Access and Compassionate Use:

  • Explore new models for simplified and accelerated access to investigational medicine from start to finish
  • Enhance global protocol development and analyze country-specific regulations
  • Benefit from physician collaboration models for advancing access to lifesaving therapies
  • Navigate the pricing, payment and reimbursement policy for MAPs
  • Discuss strategies for successful managed access programs
  • Articulate and publish MAP policy/position to align stakeholders
  • Leverage social media for advocacy, access and awareness
  • Enhance patient forecasting to maintain a robust product supply
  • Share inspiring stories, obstacles surpassed and innovative efforts in the pipeline

Plus! Tour the Complex Regulatory Landscape During our World Showcase: “Navigate Country-Specific Regulations for Extending Treatment Globally”

16-17 May, 2018 | London, England

Managed Access Programmes

Navigate Country-Specific Regulations and Optimize Global Models for Stakeholder Collaboration, Program Design and Supply Equity

CBI’s Managed Access Programs is dedicated to the nuances and complexities of designing and implementing early access programs. Focused on global considerations for a variety of access management programs, including, but not limited to: Expanded Access Programs, Early Access Programs, Compassionate Use Programs, Named Patient Programs and Managed Access Programs.

A broad array of key stakeholders are coming together for an in-depth and meaningful discussion on Managed Access Programs where the implications, prevailing policies and current industry approaches are discussed in detail. Don’t miss the opportunity to join your peers and share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes.

Advanced Discussions on Key Issues and the Path Forward for Early Access and Compassionate Use:

  • Explore new models for simplified and accelerated access to investigational medicine from start to finish
  • Enhance global protocol development and analyze country-specific regulations
  • Benefit from physician collaboration models for advancing access to lifesaving therapies
  • Navigate the pricing, payment and reimbursement policy for MAPs
  • Discuss strategies for successful managed access programs
  • Articulate and publish MAP policy/position to align stakeholders
  • Leverage social media for advocacy, access and awareness
  • Enhance patient forecasting to maintain a robust product supply
  • Share inspiring stories, obstacles surpassed and innovative efforts in the pipeline

Plus! Tour the Complex Regulatory Landscape During our World Showcase: “Navigate Country-Specific Regulations for Extending Treatment Globally”

16-17 May, 2018 | London, England